Mithrl
Mithrl provides Eos, an agentic AI Scientific Decision Engine that accelerates multi-omics analysis for biopharma and biotech R&D teams, enabling scientists to convert raw omics data into reproducible insights and novel IP in days rather than months.
- Company typePrivate
- Founded2023
- HeadquartersSan Francisco, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Mithrl does
Mithrl is a San Francisco-based enterprise AI software company founded in 2023 that operates Eos, a Scientific Decision Engine platform purpose-built for biopharmaceutical and biotechnology R&D teams. The platform targets the bottleneck in modern biology where multi-omics data generation has outpaced the ability of research organizations to synthesize actionable, reproducible insights, serving enterprise biopharma R&D organizations, clinical-stage biotech companies developing gene and cell therapies, and precision oncology research teams that need to accelerate the path from raw data to defensible decisions and novel intellectual property.
Mithrl firmographics
Firmographics- Name
- Mithrl
- Legal name
- Mithrl Inc.
- Website
- https://www.mithrl.com/
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Mithrl provides Eos, an agentic AI Scientific Decision Engine that accelerates multi-omics analysis for biopharma and biotech R&D teams, enabling scientists to convert raw omics data into reproducible insights and novel IP in days rather than months.
- Ownership category
- akta.pro rank
Mithrl industry classification
Industry- Product category
- Biomedical AI Research Platform
- NAICS
- Custom Computer Programming Services (541511), Computer Systems Design Services (541512)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- EDA Software Platforms (Digital Implementation, Verification & Signoff) (HDAHAFAA)
- akta.pro secondary industry
- EDA Cloud/SaaS, Design Data Management & Collaboration (HDAHAFAJ)
Keywords
Where Mithrl is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Mithrl business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Operations
Revenue model
- Enterprise Software Subscription: SaaS subscription model with annual or multi-year terms. Fees specified in Order Forms, with invoicing and payment terms outlined in Master Subscription Agreement. Enterprise customers pay recurring subscription fees based on agreed terms.
- Free Trial Services: Limited free trial access to services, allowing prospective customers to evaluate before purchasing. Trial period has defined end date and may result in conversion to paid subscription.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise subscription with custom pricing |
| Freemium | Pay-as-you-go | Free Trial Services |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Mithrl product offering
Product offeringCore offering
Mithrl builds and sells Eos, an enterprise SaaS Scientific Decision Engine for biopharma and biotech R&D teams. Eos is an agentic AI platform with a natural language interface, multi-agent orchestration, and proprietary knowledge graph technology that turns raw multi-omics data into reproducible, auditable insights in days rather than months. It is sold on annual subscriptions via custom Order Forms with an optional free trial.
Product overview
Mithrl offers a single unified product called Eos, which serves as the Scientific Decision Engine for enterprise R&D teams in biopharma and biotech. Eos is a purpose-built biomedical AI platform that combines agentic AI capabilities with proprietary data schemas, multi-agent orchestration, and knowledge graph technology to accelerate the discovery loop. The platform enables bench scientists and computational biologists to move from raw omics data to reproducible insights and defensible IP opportunities through natural language interfaces, without requiring deep programming expertise.
Differentiator
Problem solved
Functional benefit
Products and services
- Eos Mithrl's flagship enterprise Scientific Decision Engine platform for biopharma and biotech R&D teams. Eos is an agentic AI platform with a natural language interface, multi-agent orchestration, and proprietary knowledge graph technology that turns raw multi-omics data into reproducible, auditable insights in days rather than months. It enables bench scientists and computational biologists to move from raw omics data to defensible insights and novel IP opportunities without requiring deep programming expertise, and is sold via annual subscriptions under custom Order Forms.
Quantifiable outcome
- 32X faster on average R&D cycle acceleration
- +4 more outcomes
Companies that use Mithrl
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
Mithrl technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability7 records
Feature5 records
Mithrl partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Elephas Biosciences CorporationcoreScientific collaboration to combine Elephas's elive™ ex vivo tumor profiling platform with Mithrl's Scientific Decision Engine for accelerated discovery of novel immunotherapy response signals. Companies co-present data at AACR 2026 demonstrating integration of functional tumor profiling with AI-driven multi-modal analysis. The partnership addresses the challenge that only 1 in 5 patients receiving immunotherapy obtain a response while biopharma spends over $250 billion annually on R&D.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
Mithrl competitors and assessment
Company assessmentEmerging players
- Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology with machine learning to identify novel therapeutics. Comparable as a techbio player using multi-modal biological data and proprietary AI to compress R&D cycles, though Recursion is also a pipeline owner rather than purely a software vendor.
- Valo Health: AI-driven drug discovery platform that combines human-centric data, computation, and biology to accelerate therapeutic development end-to-end. Comparable in applying multi-agent-style AI to compress the discovery-to-development cycle for pharma-grade programs.
- Insitro: Machine learning-driven drug discovery company that integrates high-throughput biology with predictive models for target identification and IND-enabling work. Comparable in applying agentic-style ML to biomedical R&D decision-making and in the idea-to-IND acceleration mission.
- Owkin: AI biotech applying multimodal data and federated learning to oncology and other therapeutic areas, with both platform and pipeline assets. Comparable in combining multi-omics analysis with AI-driven decision support targeting pharma R&D and clinical research.
Direct peers
- Causaly: AI knowledge platform for biomedical research that surfaces non-obvious connections across scientific literature and biological evidence to support target discovery and drug development decisions. Directly comparable as an AI-driven 'scientific decision' layer for biopharma R&D teams.
- Benchling: Cloud-based life sciences R&D platform used by hundreds of biotech and pharma companies to manage experiments, sequences, and biological data. Most direct comparable as an enterprise SaaS platform targeting biopharma R&D workflows, with broader scope across ELN, registry, and analytics.
- Dotmatics: Scientific informatics platform for life sciences R&D covering data management, analysis, and decision support across the drug discovery workflow. Directly comparable as an enterprise SaaS vendor serving biopharma with workflows that turn raw experimental data into scientific insights.
- TetraScience: Scientific data cloud and AI platform purpose-built for life sciences R&D, harmonizing raw experimental data from instruments and workflows into analysis-ready formats. Closely comparable in addressing the data-to-insight bottleneck in pharma and biotech R&D with an enterprise SaaS model.
Broad incumbents
- Ginkgo Bioworks: Public synthetic biology platform serving pharma, agriculture, and industrial biotech customers with engineered biology services and codebase-driven R&D. Comparable as a platform vendor enabling biotech R&D customers to outsource complex biological workflows, though with a wet-lab rather than purely software model.
- Schrödinger: Public computational chemistry and materials science platform serving pharma and biotech R&D with physics-based modeling, predictive analytics, and collaborative software. Comparable as an established enterprise SaaS + services vendor accelerating pharmaceutical discovery with scientific rigor.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Mithrl social profiles
Digital presenceMithrl financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mithrl leadership team
Management profileNumber of profiles
Profiles11 records
Mithrl funding detail
Funding detailFunding overview
Funding rounds2 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mithrl M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mithrl
What does Mithrl do?
Mithrl builds and sells Eos, an enterprise SaaS Scientific Decision Engine for biopharma and biotech R&D teams. Eos is an agentic AI platform with a natural language interface, multi-agent orchestration, and proprietary knowledge graph technology that turns raw multi-omics data into reproducible, auditable insights in days rather than months. It is sold on annual subscriptions via custom Order Forms with an optional free trial.
Is Mithrl a public or private company?
Mithrl is a private company. It is classified as venture growth investor backed and is currently operating.
When was Mithrl founded?
Mithrl was founded in 2023. It employs 11 to 50 people.
Where is Mithrl based?
Mithrl is headquartered in San Francisco, United States, in the North America region.
How does Mithrl make money?
Two revenue lines are on record. Enterprise Software Subscription is the primary driver. The others are free Trial Services.
Who are Mithrl's main competitors?
Emerging players on record are Recursion Pharmaceuticals, Valo Health, Insitro and Owkin. Direct peers are Causaly, Benchling, Dotmatics and TetraScience. Broad incumbents are Ginkgo Bioworks and Schrödinger.
Does Mithrl have an API?
No public API is recorded for Mithrl.
What industry is Mithrl in?
Mithrl's product category is Biomedical AI Research Platform. Its primary akta.pro industry code is HDAHAFAA, EDA Software Platforms (Digital Implementation, Verification & Signoff), with a secondary code of HDAHAFAJ, EDA Cloud/SaaS, Design Data Management & Collaboration. Its NAICS code is 541511 and its SIC code is 7372.